Repligen Corporation

Repligen Corporation is a prominent life sciences company dedicated to developing and commercializing innovative bioprocessing technologies and systems that are critical for the production of biologic drugs. The company's comprehensive portfolio addresses key stages of the biopharmaceutical manufacturing process, from upstream cell culture to downstream purification and analytics. Repligen's offerings include essential components like Protein A ligands, which are fundamental for the purification of therapeutic proteins, and advanced cell culture growth factors that enhance productivity. A significant part of their business involves chromatography solutions, notably the OPUS line of pre-packed and smaller-scale columns designed for efficient purification and process development. Furthermore, Repligen provides a range of filtration products, including XCell ATF Cell Retention Systems for upstream perfusion and TangenX flat sheet cassettes for downstream concentration and buffer exchange, alongside various tangential flow filtration systems. Their process analytics segment offers sophisticated solutions like slope spectroscopy systems under brands such as SoloVPE, FlowVPE, and FlowVPX, enabling real-time monitoring and optimization of bioprocesses. Serving a global clientele that includes leading biopharmaceutical companies, diagnostics firms, contract manufacturing organizations, and academic researchers, Repligen plays a vital role in accelerating the development and commercialization of life-saving therapies by enhancing the efficiency, yield, and quality of biologic manufacturing. The company strategically focuses on acquiring and developing technologies that address unmet needs in the rapidly evolving bioprocessing landscape.